These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 15497908)

  • 41. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of a new, oral estradiol acetate formulation for relief of menopause symptoms.
    Speroff L; Haney AF; Gilbert RD; Ellman H;
    Menopause; 2006; 13(3):442-50. PubMed ID: 16735941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of acupuncture and oral estradiol treatment of vasomotor symptoms in postmenopausal women.
    Wyon Y; Wijma K; Nedstrand E; Hammar M
    Climacteric; 2004 Jun; 7(2):153-64. PubMed ID: 15497904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study.
    Nahas EA; Nahas-Neto J; Orsatti FL; Carvalho EP; Oliveira ML; Dias R
    Maturitas; 2007 Nov; 58(3):249-58. PubMed ID: 17913408
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms.
    Mizunuma H
    Climacteric; 2011 Oct; 14(5):581-9. PubMed ID: 21848497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Nielsen T; Christiansen C
    Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
    Rowan JP; Simon JA; Speroff L; Ellman H
    Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.
    White WB; Hanes V; Chauhan V; Pitt B
    Hypertension; 2006 Aug; 48(2):246-53. PubMed ID: 16801478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol.
    Gass MS; Rebar RW; Cuffie-Jackson C; Cedars MI; Lobo RA; Shoupe D; Judd HL; Buyalos RP; Clisham PR
    Maturitas; 2004 Oct; 49(2):140-7. PubMed ID: 15474758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study.
    Abdali K; Khajehei M; Tabatabaee HR
    Menopause; 2010 Mar; 17(2):326-31. PubMed ID: 20216274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms.
    Speroff L; Symons J; Kempfert N; Rowan J;
    Menopause; 2000; 7(6):383-90. PubMed ID: 11127760
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
    Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
    Hudita D; Posea C; Ceausu I; Rusu M
    Eur Rev Med Pharmacol Sci; 2003; 7(5):117-25. PubMed ID: 15214586
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormone replacement therapy with estradiol and drospirenone: an overview of the clinical data.
    Whitehead M
    J Br Menopause Soc; 2006 Mar; 12 Suppl 1():4-7. PubMed ID: 16513012
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
    White WB; Pitt B; Preston RA; Hanes V
    Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol + drospirenone and tibolone, on sexual function in healthy postmenopausal women.
    Cayan F; Dilek U; Pata O; Dilek S
    J Sex Med; 2008 Jan; 5(1):132-8. PubMed ID: 17961145
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.
    Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S
    Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis.
    Tatarchuk T; Stevenson JC; Yu Q; Kahler E; Graziano Custodio M; Ren M; Nappi RE; Karpova V; Simoncini T
    Gynecol Endocrinol; 2024 Dec; 40(1):2375577. PubMed ID: 38976762
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.